Boston, Mass. —Massachusetts Eye and Ear opened a new ophthalmology (eye care) practice at 578 Main Street in Malden, Mass., on March 6. Mass. Eye and Ear, Malden is the hospital’s 19th location designed to bring the expertise of Mass. Eye and Ear specialists to the surrounding greater Boston area.
The Malden location offers comprehensive ophthalmology, including cataract surgery and contact lenses, as well as eye plastics services. The practice office also
Boston, Mass. — Researchers from Schepens Eye Research Institute of Massachusetts Eye and Ear have uncovered two factors responsible for the chronic, lifelong nature of autoimmune disorders, which tend to “flare up” intermittently in affected patients. These two factors are cell-signaling proteins called cytokines—specifically Interleukin-7 and -15 (IL-7 and IL-15)—that are secreted by cells of the immune system and help modulate memory Th17 cells, a subset of T cells which are known to contribute to autoimmune disorders. Until now, it was unclear how Th17 cells
Boston, Mass. — Luk H. Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and an Assistant Professor of Ophthalmology at Harvard Medical School, has been awarded a Nelson Trust Award for Retinitis Pigmentosa by Research to Prevent Blindness (RPB) in the amount of $100,000 over two years. The Nelson Trust Award was established to stimulate, strengthen and accelerate research to improve
Information for this release was provided by the Association for Research in Vision and Ophthalmology.
Rockville, Md. — Vision scientists may have discovered how to reduce pedestrian collisions in crowded and chaotic open space environments like bus terminals, shopping malls and city plazas involving individuals with partial blindness. Researchers have determined from which direction collisions with partially blind pedestrians are most likely to originate. This understanding will guide the development of new glasses that expand the sight of a person
Ophthalmologists at Mass. Eye and Ear among the most experienced nationwide with newly FDA-approved corneal cross-linking procedure
Boston, Mass. — Ophthalmologists at Massachusetts Eye and Ear are currently accepting patients who may be candidates for a newly FDA-approved outpatient procedure known as “corneal cross-linking.” Corneal cross-linking is a stabilizing treatment to halt the progression of keratoconus, a
New findings may pave the way for the development of pharmaceutical therapies to reverse corneal scarring
Boston, Mass. — In cases of severe ocular trauma involving the cornea, wound healing occurs following intervention, but at the cost of opaque scar tissue formation and damaged vision. Recent research has shown that mesenchymal stem cells (MSCs) — which can differentiate into a variety of cells, including bone, cartilage, muscle and fat cells — are capable of returning clarity to scarred corneas; however, the mechanisms by which
Boston, Mass. — Researchers at Massachusetts Eye and Ear have discovered a new mutation in a highly antibiotic-resistant strain of E. coli that resists clearance by the body’s own immune system by inhibiting white blood cells that ordinarily kill and remove bacteria. In a paper published online today in JAMA Ophthalmology, the researchers describe the case that led them to
Findings published in the American Journal of Pathology offer new directions for treatment of patients with Fuchs’ Endothelial Corneal Dystrophy (FECD)
Boston, Mass. — Researchers from Massachusetts Eye and Ear have, for the first time, identified rapidly proliferating cells (known as “neural crest-derived progenitor cells”) in the corneal endothelium of specimens from normal corneas and from corneas with Fuchs’ Endothelial Corneal Dystrophy (FECD), a condition in which the cells responsible for keeping the cornea
The strategic licensing agreement between Lonza and Massachusetts Eye and Ear® underscores Lonza’s position as a leading AAV manufacturing service provider and offers customers unprecedented technology and services to commercialize next generation gene therapies.
The Anc-AAV vector platform has the potential to overcome pre-existing immunity in order to treat more patients compared with other viral vectors currently in development.
Anc80, the lead novel Anc-AAV available for sublicensing, is a potent gene therapy vector capable of superior gene expression levels in